Retatrutide

Triple Incretin Receptor Agonist | GLP-1 + GIP + Glucagon for Advanced Fat Loss & Metabolic Optimization

Overview:

Retatrutide is a next-generation triple incretin agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and Glucagon receptors simultaneously. This unique triple-action mechanism offers a powerful blend of appetite suppression, fat oxidation, and energy regulation, positioning Retatrutide at the forefront of advanced weight management and metabolic enhancement therapies.

This product is supplied as a lyophilized powder and requires reconstitution before use.

Key Benefits:

• Promotes deep, sustained fat loss through increased metabolic rate

• Strong appetite and craving suppression

• Enhances insulin sensitivity and glycemic control

• Supports lipid metabolism and energy balance

• Once-weekly subcutaneous dosing for convenience

Reconstitution Instructions:

• Reconstitute using Bacteriostatic Water (BAC)

• Example: Add 2mL of BAC to a 5mg vial for a 2.5mg/mL solution

• Gently swirl (do not shake) until dissolved completely

• Store reconstituted Retatrutide in the refrigerator (2–8°C)

Dosing Guidelines:

• Initial dose: start low (e.g., 0.25–0.5mg weekly)

• Therapeutic range: 1–5mg+ weekly, titrated based on tolerance and goal

• Administer via subcutaneous injection (abdomen, thigh, or upper arm)

• Duration: 12–24 weeks typical for significant body composition changes

Monitoring & Considerations:

• Common side effects: Nausea, fullness, slowed digestion, mild fatigue (usually temporary)

• Monitor: Blood glucose, hydration, GI tolerance, and lipid markers

• Contraindications: History of medullary thyroid carcinoma (MTC) or MEN2 syndromes

Note: Retatrutide is designed for individuals seeking an aggressive yet clinically supported fat-loss solution. Its triple-action profile delivers compounded benefits over traditional single-pathway agents, making it ideal for high-response protocols and advanced metabolic interventions.